Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04067960 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 197
- Enrollment target
NCT04067960: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT04067960 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 197 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04067960, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 197 participants
- Enrollment target
Study Summary
This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer. Pharmacogenomics is the study of how genes may affect the body's response to and interaction with some prescription medications. Genes, which are inherited from parents, carry information that determines things such as eye color and blood type. Genes can also influence how patients process and respond to medications. Depending on the genetic makeup, some medications may work faster or slower or produce more or fewer side effects. Pharmacogenomics testing may help doctors learn more about how patients break down and process specific medications based on their genes and improve the quality of life of cancer patients receiving clinical care.
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- OTHER Genetic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2019-06-06 |
| Est. Completion | 2022-10-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04067960
The ClinicalTrials.gov registry entry for NCT04067960 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT04067960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04067960 about?
NCT04067960 is a clinical study titled "Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer". This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer. Pharmacogenomics is the study of how genes may affect the body's response to and interaction with some prescription...
What is the current status of trial NCT04067960?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 197 participants. The study started on 2019-06-06. Estimated completion is 2022-10-06.
What interventions are being tested in trial NCT04067960?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Genetic Testing (OTHER).
Who is sponsoring clinical trial NCT04067960?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.